Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rubitecan: Phase II data; Phase III

SUPG reported data from a Phase II trial of rubitecan in 58 pancreatic cancer patients who failed prior treatments.

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE